Who is 4SC?

Headquartered in Planegg-Martinsried near Munich/Germany, 4SC is an innovative biopharmaceutical company with a strong focus on product development in oncology. We develop novel small molecule drugs for the treatment of cancer in indications with a high unmet medical need and significant economic potential.

Why choose 4SC drugs?

Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life. 4SC’s current product pipeline includes two programs in clinical development: resminostat and domatinostat.

What is the 4SC product pipeline?

The 4SC product pipeline currently comprises two drug candidates in clinical development, resminostat and domatinostat, and a third compound, 4SC-208, that is in pre-clinical development.

How does 4SC make money?

Through resulting license fees, milestone payments and royalties, and direct sales revenues, 4SC aims to achieve sustainable revenue growth and profitability.